A Phase 1 Dose Escalation Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors

Trial Profile

A Phase 1 Dose Escalation Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2007

At a glance

  • Drugs PPI 2458 (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Jul 2007 Status changed from in progress to discontinued.
    • 01 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top